Related Experiment Video
Updated: Jun 10, 2025

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
Published on: March 6, 2019
Clinical Effect of Descent in Infants with Bronchiolitis Diagnosed at Altitude: A Prospective Multicenter Study
Anne Poirier1,2, Amélie Basso3, Sarah Bonnet-Ducrot3
1Pediatrics Department, Métropole Savoie Hospital (CHMS), Chambéry, France.
Abstract:
Poirier, Anne, Amélie Basso, Sarah Bonnet-Ducrot, Ellen Katranji, Sophia Cherif-Alami, Sophie Chateigner-Coelsch, Manon Navarre, Cécile Ricard, and Corentin Tanné. Clinical effect of descent in infants with bronchiolitis diagnosed at altitude: a prospective multicenter study. High Alt Med Biol. 26:134-139, 2025. Objective: This study aims to assess the clinical impact of descending to a lower altitude in infants with bronchiolitis diagnosed at an altitude above 1,000 m. Methods: We performed a prospective, observational, multicenter study during two consecutive winters (2022-2023 and 2023-2024). The diagnosis was made by local general practitioners (GPs) who then sent the patients who were younger than 1 year and had a Wang respiratory score (WRS) ≥4 to any of the five emergency departments (EDs) located at lower altitudes. The WRS, peripheral oxygen saturation (SpO2), and respiratory rate (RR) recorded by the GPs and at the EDs were compared. Results: We included 74 infants (59% females, median age 5.4 [3.6-8.0] months). Compared with the median values recorded by the GPs at altitudes above 1,000 m, the median values at the lower-altitude EDs were significantly better for the WRS (5.0 vs. 6.0, p = 0.002), RR (50/min vs. 60/min, p = 0.001), and SpO2 (97.0% vs. 91.5%, p < 0.001). Conclusion: Descending to a lower altitude significantly improved respiratory function in infants younger than 1 year with bronchiolitis diagnosed at altitudes above 1,000 m.
Related Concept Videos
Pulmonary Cycle: Exhalation
Acute Respiratory Failure-IV
Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Breathing
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
COPD: Management Using Bronchodilators and Corticosteroids

